| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 206.475.858 $ | +29.559.783 $ | +1,2 % | 8 | 176.916.075 $ | +308.870 $ | -1,9 % | 7 | 176.607.205 $ | +176.607.205 $ | 5 | |||||
| KESTRA MEDICAL TECHNOLOGIES, LTD. | KMTS | → 0 | Neutral | 69.417.594 $ | +15.702.417 $ | +29,2 % | 1 | 53.715.177 $ | -13.648.434 $ | -20,3 % | 1 | 67.363.611 $ | +67.363.611 $ | 1 | |
| Mineralys Therapeutics, Inc. | MLYS | → 0 | Neutral | 42.949.921 $ | -175.111 $ | -0,4 % | 1 | 43.125.032 $ | -14.645.636 $ | -25,4 % | 1 | 57.770.668 $ | +57.770.668 $ | 1 | |
| Evommune, Inc. | EVMN | → 0 | Neutral | 18.499.547 $ | -25.120.805 $ | -57,6 % | 1 | 43.620.352 $ | +11.137.515 $ | +34,3 % | 1 | 32.482.837 $ | +32.482.837 $ | 1 | |
| Avalyn Pharma Inc. | AVLN | → 0 | 30.609.806 $ | +30.609.806 $ | 1 | ||||||||||
| Agomab Therapeutics NV | AGMB | → 0 | Schwach | 19.972.352 $ | +3.831.368 $ | +23,7 % | 1 | 16.140.984 $ | +16.140.984 $ | 1 | |||||
| Inventiva S.A. | IVA | → 0 | Schwach | 13.733.424 $ | +3.642.519 $ | +36,1 % | 1 | 10.090.905 $ | +1.636.363 $ | +19,4 % | 1 | 8.454.542 $ | +8.454.542 $ | 1 | |
| Abivax S.A. | ABVX | → 0 | Schwach | 10.410.938 $ | +1.711.719 $ | +19,7 % | 1 | 8.699.219 $ | -1.836.328 $ | -17,4 % | 1 | 10.535.547 $ | +10.535.547 $ | 1 | |
| Nyxoah SA | NYXH | → 0 | 882.276 $ | -642.130 $ | -42,1 % | 1 | 1.524.406 $ | +1.524.406 $ | 1 | ||||||
| 206.475.858 $ | +29.559.783 $ | +1,2 % | 8 | 176.916.075 $ | +308.870 $ | -1,9 % | 7 | 176.607.205 $ | +176.607.205 $ | 5 | |||||